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Abstract 
Clinical trials (CT) in breast cancer have been crucial for new treatment discoveries. While participation in 
cancer CT is low, minorities are particularly underrepresented.This study aimed toidentify factors 
influencing the participation in CTs based on the experiences of Latina breast cancer survivors in Puerto 
Rico (PR), especially their CT knowledge, motivations, and concerns.Method:Focus groups (FG) were 
conducted by two social workers and the University of Puerto Rico/MD Anderson Community Health 
Educator. Participants were stratified into two subgroups: a) women with CT experience and b) those 
without CT experience. Seven FG were completed among breast cancer survivors (n=34) at two hospitals 
from the PR metropolitan area. Results: Our findings showed that participants expressed a basic 
knowledge and understanding of clinical trials. Motivations to participate included a desire to help others, 
non-monetary incentives to participation, self-benefits, readiness to participate based on the phases of 
illness, and enhanced relationships with the clinical trial recruitment team. Regardless of their previous 
experience with CTs, participants expressed concerns about participation including limited of knowledge 
about trial procedures and results, and lack of transportation, childcare, and support from family. 
Recommendations: The barriers and motivations identified for CT participation are modifiable and best 
targeted using a multidisciplinary approach.Social workers could play a potential role in participant 
recruitment and retention by clarifying research protocols to potential participants, as well as conducting 
CT. Our findings can help enhance capacity and training efforts for health professionals involved in CT 
recruitment and retention in culturally-relevant ways. 
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 Clinical trials (CT) in breast cancer have been crucial for new treatment discoveries. While 
participation in cancer CT is low, minorities are particularly underrepresented. This study aimed 
to identify factors influencing the participation in CTs based on the experiences of Latina breast 
cancer survivors in Puerto Rico (PR), especially their CT knowledge, motivations, and concerns. 
Method: Focus groups (FG) were conducted by two social workers and the University of Puerto 
Rico/MD Anderson Community Health Educator. Participants were stratified into two subgroups: 
a) women with CT experience and b) those without CT experience. Seven FG were completed 
among breast cancer survivors (n=34) at two hospitals located in Caguas and San Juan, PR. 
Results: Our findings showed that participants expressed a basic knowledge and understanding of 
clinical trials. Motivations to participate included a desire to help others, non-monetary incentives 
to participation, self-benefits, readiness to participate based on the phases of illness, and enhanced 
relationships with the clinical trial recruitment team. Regardless of their previous experience with 
CTs, participants expressed concerns about participation including limited of knowledge about 
trial procedures and results, and lack of transportation, childcare, and support from family. 
Recommendations: The barriers and motivations identified for CT participation are modifiable 
and best targeted using a multidisciplinary approach. Social workers could play a potential role in 
participant recruitment and retention by clarifying research protocols to potential participants, as 
well as conducting CT. Our findings can help enhance capacity and training efforts for health 
professionals involved in CT recruitment and retention in culturally-relevant ways. 
Keywords: Breast Cancer Survivor, Clinical Trials, Latinas, Hispanic, Puerto Rico 
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INTRODUCTION 
Clinical trials research in cancer is essential for the development of effective prevention, 
diagnostic, and treatment methods. Ethnic and racial minorities and underserved populations are 
particularly underrepresented in clinical trials in the United States (US) (Advani et al., 2003; 
Brown, & Topcu, 2003; Ford et al., 2013; Moreno-John et al., 2004; Murthy, Krumholz, & Gross, 
2004; Powell, Fleming, Walker-McGill, & Lenoir, 2008; Yancey, Ortega, & Kumanyika, 2006). 
It is estimated that less than 5% of cancer patients participate in clinical trials, and that racial and 
ethnic minorities are disproportionately underrepresented compared to non-Hispanic Whites 
(Fracasso et al., 2013). Only 2.0–4.0% of clinical trial participants self-identify as Latino 
(Kwiatkowski, Coe, Bailar, & Swanson, 2013; Parra, Karnad, & Thompson, 2014). This 
underrepresentation of Latino populations in clinical trials hampers the generalizability of trial 
results, such as new treatments or interventions that may be relevant to this population and 
contributes to inequitable distribution of benefits and risks of trial participation among these 
populations.  
Researchers have explored factors influencing Latino participation in trials (Arevalo et al., 
2016; Calderón et al., 2006; Ellington, Wahab, Martin, Field, Mooney, 2006; Ford et al., 2013; 
Nodora, O’Day, Yrun, & García, 2010). Results have suggested that factors associated with their 
participation include knowledge, awareness, age, comorbidities, socioeconomic status, fears, 
research mistrust, and logistic barriers, such as transportation and time constraints (Arevalo et al., 
2016; London et al., 2015). Studies exploring clinical trial participation in Puerto Rico (PR) are 
scarce. This is despite the burden of breast cancer in PR, as well as, the controversial history of 
clinical trials among Puerto Rican women (Vargas, 2017). 
Breast cancer is the leading incidence and mortality cancer among Puerto Rican women. 
The number of Puerto Ricans living with breast cancer in 2010 was estimated to be 13,736 women 
(Centeno-Girona et al., 2013); thus, it is important to understand patients’ knowledge, barriers and 
facilitators that might help or interfere with participation of Puerto Rican women in breast cancer 
clinical trials. An enhanced understanding of these factors is necessary to design strategies that 
will aid in increasing recruitment and retention of participants in future clinical trials. Moreover, 
it is also necessary to explore whether or not these factors differ among women with and without 
clinical trial experience because it could aid in identifying opportunities to increase recruitment 
and retention of these two populations. The general purpose of this qualitative study was to identify 
the knowledge, motivations, and concerns influencing CT participation of Latinas in PR, including 
those with and without prior clinical trial participation experience. The specific aims of the study 
were: a) To identify factors (individual, cultural, social, and economic) influencing clinical trial 
participation and recruitment among breast cancer women survivors in PR; b). To explain issues 
surrounding willingness or unwillingness to participate in Cancer clinical trials; c) To describe the 
most common concerns and questions asked about an ongoing cancer clinical trial; and d) To 
explore clinical trial satisfaction, and willingness or unwillingness for future participation among 
breast cancer women survivors with clinical trial participation experience. 
 
METHODS 
Study Population  
An interdisciplinary research team consisting of epidemiologists, social workers, and a 
community health educator (CHE) recruited participants from two hospitals located in Caguas and 
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San Juan, PR. Previous research collaborations existed between our research team and hospital 
institutions because these institutions provide health services to women with breast cancer 
diagnosis. Individuals were eligible to participate if they were: 1) Spanish speakers; 2) women; 3) 
21 years of age and older, and 4) had been previously diagnosed with breast cancer. Participants 
were identified by the hospitals. Those that agree to participate were subsequently referred to the 
research team. Research assistants contacted women that agree to participate and confirmed the 
women’s participation in this study by phone. 
Study Design & Procedures 
Focus groups (FG) were conducted in Spanish by two social workers and the University of 
Puerto Rico/MD Anderson Community Health Educator (CHE), all of whom were trained in 
qualitative methods. Two groups of breast cancer survivors were included in the FG: (1) women 
who had previously participated in a clinical trial and, 2) women who had not participated. Study 
participants reviewed and signed an informed consent and completed a brief survey including 
questions regarding their sociodemographic, cancer clinical history, and their previous experience 
with clinical trials, when applicable. Each FG had approximately five participants in each group. 
Four (4) FGs were conducted with participants who had participated in clinical trials, and three (3) 
FGs with participants without clinical trial participation experience. All FGs were audio recorded, 
lasting approximately 90 minutes. During the FG conversations, participants were asked to share 
their experiences and perceptions of clinical trials using a semi-structured interview guide 
addressing as summarized in Table 1. Upon completion, each participant received an incentive of 
$20.00 for their time and transportation costs. The Institutional Review Board of the University of 
PR, Medical Sciences Campus reviewed and approved the study protocol. 
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Table 1: Questions of the FGs, and topics* 
 
Aims: 







• What do you know about clinical trials?  
• Have you ever been invited to participate in a breast cancer clinical 
trial or other type of clinical trial?  
• Would anyone like to share their experience from trials you have 
participated in? (WE) 
• If you were invited to participate in a clinical trial, what reasons 
would motivate you to participate?  
• If you are invited to participate in a clinical trial again, what reasons 
would motivate you to participate? (WE) 
• What opinion do you have in general about people that participate 






• (An example of a clinical trial is presented to the participants of 
FGs). As a result of the previously described research protocol, 
what questions do you have about this clinical trial?  
• If we ask you to participate in this clinical trial, what reasons would 
you have to participate in this clinical trial? 
• What reasons do you think could influence your decision to 
participate in this clinical trial?  




• What are the things that would make difficult your participation in 
a clinical trial?  
• What are the things that would facilitate your participation in a 
clinical trial?  
• Which reasons do you understand will influence your decision to 
participate in a clinical trial?  
• Why do you think that clinical trials are important for you and your 
family?  
• If you have children, what reasons would you have to register them 
in a clinical trial?  
• What kind of research related with cancer do you think should be 








•  Have you ever seen or listened any social media or promotion of a 
specific clinical trial? (Explore details) 
• Let’s assume that we want to develop educational materials to 
increase the knowledge and recruitment of breast cancer survivors 
in clinical trial, like the example mentioned before, what 
information do you think is necessary to include in the 
informational material to help people decide to participate?  
* WE refers to women with clinical trial experience. 
 Analysis 
Triangulation technique, peer debriefing, and negative case analysis were applied for 
credibility as recommended in the literature (Barush, Gringeri, & George, 2011). After each FG 
section, a peer debriefing short meeting was implemented to discuss systematically the FG’s 
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experience and explore researchers’ perspectives and thoughts. A research assistant transcribed all 
of the Spanish audio recordings of FG conversations ad verbatim, and another staff member 
revised the transcripts for accuracy. After all the data was transcribed, the research team conducted 
a process of triangulation of peer’s analysis (Strauss, 2003). This type of triangulation involved 
five researchers from different disciplines, who were trained in coding and analyzing FGs, and 
were non-blinded to the purpose of the study. They were asked to code the first two transcripts 
independently, identifying major themes according to the aim of the study. Also, coders were 
encouraged to identify emergent new themes. This allowed the team to confirm findings across 
researchers without prior discussion (Carter et al., 2014; Denzin, 1978; UNAIDS, 2010).  Then, 
the team came together to determine similarities and differences in the coding process and define 
themes combining the multiple discussions (Barush, Gringeri & George, 2011). Coders are 
described as interdisciplinary researchers that were directly involved in the data collection process 
as well other research assistants not involved. A preliminary data codebook was developed for this 
initial phase of the analysis. Three specific themes were identified that contribute to understand 
patients’ knowledge, barriers and facilitators that might help or interfere with participation of 
Puerto Rican women in breast cancer clinical trials. Subsequent weekly research team meetings 
were conducted to apply this triangulation technique with all the transcripts. If negative case 
analysis emerged, it was integrated into the discussion to critically question the pattern of 
responses identified among other participants. Once the group reached consensus, the thematic 
data analysis was entered into the Nvivo software version 11 to begin linking codes and associate 
quotations for all transcripts. Similarities and differences were intended to be identified between 
groups with previous clinical trial experiences and without clinical trial experiences. This paper 
organized findings into the three major themes: 1) knowledge about clinical trials; 2) motivations 
to participate; and 3) concerns to participate in a trial (See table 2).  
 
Table 2: Themes and definitions as part of the analysis  
Themes  Definitions 
Knowledge about 
clinical trials 
The information that participants had about clinical trials (ex. 
definitions, descriptions about clinical trial processes, etc.). 
Motivations to 
participate 
The elements that promote or facilitate the participation of women's 
breast cancer survivors in clinical trials. In our study, it included the 
reasons Latinas provided for participation in future clinical trials. It 
includes the following 5 subcategories: a) help to others, b) 
incentives, c) self-benefits, d) phases of illness: diagnosis, treatment, 




Issues, general concerns, or barriers to participate in clinical trials. It 
includes the following 5 subcategories: a) Implications of the 
experimental intervention, b) Lack of access to results, c) Lack of 
knowledge of the clinical trial protocol and adverse effects, and d) 
Historical memory of clinical trial experiences. 
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RESULTS 
Demographics  
A total of seven FGs (n=34) were conducted. Four of them were conducted with 
participants with clinical trial experience and three FGs with participants without clinical trial 
experience. Across all the seven groups, more than the half (61.7%) of the women were married 
or cohabitating; 64.7% had some years of college or a college degree; and 63.6% had an annual 
household income below $34,999. More than the half of the women (64.7%) had private health 
insurance (See table 3). 
Breast Cancer Treatment Experiences  
A vast majority (82.4%) of the women reported that they had had difficulty with medical 
insurance to receive services related to their breast cancer treatment and 57.6% were currently in 
breast cancer treatment at the time of study. More than the half of the women (61.7%) used their 
personal car as transportation method for appointments (See table 3).  
Clinical Trial Experiences 
A total of 41.2% of all of the participants in the FGs had heard about clinical trials before 
participating in our study, 32.4% were invited to participate in clinical trials, and more than the 
half of the women (63.6%) were willing to participle in clinical trials in the future (see table 3). 
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Results of Analysis  
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The quotations obtained during the FG are presented below according to the three main 
themes used for analysis: 1) knowledge about clinical trials; 2) motivation to participate; and 3) 
concern to participate. Each quotation is identified by the number of the FG. 
1. Knowledge about clinical trials 
In general, participants expressed that clinical trials are scientific processes in which new 
treatments are developed for different illnesses. They contribute to advance the medicine and to 
identify the causes of cancer. A participant with prior clinical trial experience indicated: 
 
I do not know if I am correct, but [clinical trials] their purpose is to improve the quality of 
life of a patient with cancer. Other [purpose is] research for the future. Other, it is 
for…something related with these research studies, with these studies is that have something 
in their hands to develop it. I mean, like the most important purpose for me is advance a cure 
for cancer and advance cancer research (FG #4). 
 
Some participants also understood how the scientific method is applied to achieve the goal of the 
clinical trials. A participant without clinical trial experience expressed:  
 
I believe that a clinical trial can be detached from a hypothesis. Because the trial comes 
from a hypothesis, you seek to prove it…And depending on the results, new discoveries can 
be obtained that benefit us all. Like all of the advantages that we are now enjoying with 
the prescribed drugs, as these investigations also come from clinical trials. FG #8 
 
2. Motivation to participate 
Next, we present our findings about elements that participants indicated that would 
promote or facilitate their participation in a breast cancer trial in five sub-categories: a) help to 
others, b) incentives, c) self-benefits, d) phases of illness: diagnosis, treatment and remission, and 
e) patient and clinical trial research team's relationship. 
 a. Help to others. Participants said that they would take part in clinical trials, if doing so 
could help others, including their families. Because of their journey with breast cancer, both groups 
understand the difficulties that can be experienced and they expressed it as a motivation to take 
part in clinical trials. Regarding possible benefits, they expressed that if they could help prevent 
cancer and find better treatments with their participation, they would do it. Other participants 
expressed their gratitude towards the women that had been part of previous clinical trials, and 
recognized their duty in the development of the treatments they currently receive. Two participants 
in the FG with CT experience expressed the following: 
 
In my case, I would be motivated by the same, the possibility of helping and contributing 
to other patients who are disoriented. You know, for example, right now I have an aunt 
that just had a biopsy and we are waiting for the results. I would like to learn a little more, 
so I could help her and my family, and anyone who needs help. FG #3 
 
In my case, I thank all the people who served and participated in clinical research. For 
example, with Tamoxifen, the pill that we take in our treatments. If those women had not 
participated, I would not have been beneficiated. And that's how it goes with every 
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medicine that is on the market right now. So, I'm very grateful of these studies and to be 
able to participate. FG #4 
 
Participants without clinical trial experience indicated: 
 
Well, it's hard... When you have the condition, you say: "let's go, let's do it." Honestly, if 
you ask me now, I'd tell you: "Yes, I would participate in a research study." Before having 
cancer, I would had told you that I would not participate; I will not be a guinea pig. But 
since you go through the experience, it touches you closely and it hurts. You want to help. 
You want to help other people to prevent the disease. Actually, the word is, prevention... 
helping other people. I would accept it right now. If you asked me 7 months ago, no. FG 
#2 
 
b. Incentives. Incentives means something concrete or accommodations patients can 
receive to motivate them to participate in clinical trials. Participants in general expressed having 
access to their results during their participation to be a motivation. Neither group discussed the 
need to obtain money as a priority for their participation. Other issues, such as flexibility for 
scheduling clinical trial procedures, and access to results and health services, were also important 
and perceived as incentives for participation. Other factors to be considered to accommodate their 
participation were: employment status, geographical location, transportation, and child care. A 
participant with clinical trial experience indicated: 
 
In my experience, because I had lost a lot of work days, I could not participate of the study. 
So they went to my house on a Saturday, my free day…also the schedules; why can't clinical 
studies be conducted at nights or weekends? …I told her: "I really can't miss work." And 
she went to my house…I think it's very difficult to leave your work area for a study, and 
then go back to work if you have the time. It would have been easier for me if the study had 
been at night or on a Saturday…There are many people who do not work, but if you are a 
person who does, you have some responsibilities there, and in addition, you have to go to 
three appointments a month…The solution is "I won't do it". FG #4 
 
Another participant without clinical trial experience said: 
  
Even during the time that the group is being monitored in the trials, the research team 
should also be orienting them about how the study is going, how are the findings; because 
that motivates the person to also continue her to participate... Because I see it as you're 
trying to help me, and I'm not just another number. …you are helping me to improve and 
to overcome my situation, and I contribute as well. FG #2 
 
c. Self-benefits. Self-benefits mean something concrete patients could receive to help 
improve their own health. Some participants with clinical trial experience expressed an interest in 
knowing the results of their tests so that they could use them for their treatments, considering this as 
a self-benefit. There was also an expectation of a reduction or elimination of treatment costs and 
privilege-related priority at treatment appointments. Two participants with clinical trial experience 
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expressed the importance of knowing the causes, treatments, and alternatives as a motivation to 
consider their participation: 
 
Yes, because that is important. Because you want to help to improve the situation and 
promote the disclosure of the results for better treatments. But also, you would like to see 
how it can help you too. FG #6 
 
…I would participate in the study in the group of chemotherapy alone, if they offered me 
an incentive that guarantees me that I will not have to wait that long for treatment. And 
that because I'm part of this study, I have the benefit of having the first turn. FG #6 
 
d. Phases of illness: Diagnosis, Treatment, and Remission. Participants with clinical trial 
experience expressed concern regarding the stage of cancer in which some of them were contacted 
to participate in clinical trial. They expressed, that if the reach out process was made at times when 
they had overcome their negative emotions about their diagnosis, there was a higher possibility that 
they would participate. 
 
I would participate because I believe that when you already pass to that other stage, like 
the one that I am at now, where you already saw what happened. Before you were the 
protagonist, but now you are not, you become part of the show and you can analyze things 
without being touched in a personal way. And there you have the disposition and the 
knowledge of what touched you personally, and now you can sit in the other's seat…And 
if you're going to invite me to a study that I can contribute something that is needed, I want 
to be part of that because I have a lot to talk about. FG #6 
 
e. Patient and clinical trial research team's relationship. Participants in both groups valued 
the communication between the clinical trial research team and themselves. Women with experience 
in clinical trials, expressed their satisfaction with the process by the amount and quality of the contact 
kept by the team. Participants with no experience, manifested that if the conversations with the team 
were constant, they would consider participation. Participants with clinical trial experience reported 
that a close relationship between patients and research team was a very important element to decide 
to participate in clinical trial.  
 
…it should be done in a way that shows the humanized treatment given to the patients. 
They even went to my home on New Year's Eve and took pictures of the family sharing with 
the patient…Even the psychologists went, and I saw that the doctors were also involved…it 
was very nice. FG #5 
 
Also, participants of FGs without clinical trial experience focused on having a good relationship and 
constant conversation with the team. As part of these conversations, they expressed their interest to 
receive information about the progress of the study: 
 
That the professionals in charge of the trial keep participants informed the whole time, not 
only in the beginning, but "during the process"...I am a risk taker… I am adventurous... I 
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like to investigate things... I would even dare to participate, if I have these data, updated 
with a reasonable frequency. FG #8 
 
3. Concerns to participate 
Women in both subgroups expressed that there was some fear to be exposed to a new drug 
with unknown effectiveness. Also, concerns about socioeconomic issues such as transportation 
costs, lack of childcare (especially those taking care of grandchildren), lack of family support, and 
time invested from work to participate in clinical trials (daily activities requirements from clinical 
trials) were verbalized.  
a. Implications of the clinical trial on their health. Most of the participants found it difficult 
to decide joining a clinical trial because of the lack of information about the implications of the 
clinical trial on their own health. Some expressed their concerns about co-morbidities, the 
interaction of the clinical trial drug with their previous medications, and the capacity to be managed 
as part of the clinical trial protocol. Two participants with clinical trial experience said:  
 
“The same, the side effects, which I believe are worse than the remedy”. FG #3.  
 
But I would be questioning: "What is this for?"; the pros and cons. Right now, I have to 
ask about my medications, because I am allergic to aspirin and penicillin, and I developed 
that after I had surgery. Now, wherever I go, I have to say it. FG #5  
  
b. Lack of access to results. Concerns about the use of data collected in clinical trials and 
not having information about the research results during and after the clinical trial is completed, 
were frequently manifested as a main reason for not participating by groups with clinical trial and 
without clinical trial experience. Some of the women expressed their interest to have access to the 
clinical trial tests (i.e. genetic tests) that are very expensive, but are required by their doctors for 
their cancer treatment’s strategy. A participant with experience said:  
 
…I would think about it and maybe would not participate. Because you give and do not 
receive. Also, you will not have access to the genetic studies that could help in the future 
to solve any health situation. If I'm not going to benefit, then I don't understand, because I 
believe that one has the right to receive everything that is yours. FG #4 
 
Participant without experience: 
 
The deductible only was more than a thousand dollars. The deductible! If we talk about the 
cost, it is very high. I pay a 25%. If I'm aware that the study was already done by blood 
samples, why I cannot have access to the results? Do you understand?... It must be part of 
the same treatment of that patient, and not see it merely as a statistical result. It should be 
as a sign of commitment to that patient, who is also undergoing through medical 
improvement. FG #2  
 
  c. Lack of knowledge of the clinical trial protocol and adverse effects. Participants 
manifested some concerns about the testing group that they would be assigned to in the clinical 
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trial. They would not like to be exposed to some unnecessary or repeated treatment, and there 
could be some hesitation to participate if they could not choose. The lack of knowledge about the 
processes of the clinical trial, could be determinant to resign participation. A participant without 
clinical trial experience expressed:  
 
I would not participate, because if I will not benefit... You will not know; they will not tell 
you in which group you will be...  And the selection of the group is randomized.... because 
that's the purpose of the study, this ... it's a difficult question. FG #2 
 
d. Historical memory of clinical trial experiences. Even though participants without 
clinical trial experience recognize that the participation of other women has been crucial for the 
development of new treatments, there was a fear to be treated as guinea pigs, this is in reference 
to the birth control pill trial carried out in PR in the 1950s (De Malavé, 2005) and other historical 
trials implemented among Puerto Rican women.  
 
P03: In the past it was said that we were treated like... like I am. What was it like...?  
P02: Like Guinea Pigs? 
P03: That! (Laughs) Guinea Pigs, because they were always experimenting with us.  
            (P02 & P03) FG #1 
 
Also, some women with clinical trial experience expressed their concerns about the interests that are 
behind the development of clinical trial. There was some recurrent fear of becoming guinea pigs, 
and that they could be used for the economical and scientific advantage of the research team, instead 
of for their health.  
 
I am also worried, that sometimes…the primary interest is to obtain information from 
patients already involved in this situation. But what kind of risks can one have as a patient 
when undergoing this type of clinical trial? It favors, of course, the group that is doing the 
research. We could be like guinea pigs, because the primary interest is:  "Let's see how we 
get information, an injection, something that provides what we want to find, the last Coca-
Cola in the desert." Even though the people who are participating in the studies are already 
patients and their lives are compromised. FG #5 
 
DISCUSSION 
This qualitative study assessed knowledge, barriers and facilitating factors to increase 
clinical trial participation among Puerto Rican breast cancer survivors. The most common 
motivations for participants reported were: a) help to others, b) incentives for getting access to 
results, flexibility for scheduling clinical trials procedures, and health services, c) self-benefits, d) 
consideration of the phases of the illness: diagnosis, treatment and remission, and e) strong patient 
and clinical trial research team relationship. On the other hand, concerns about participating in 
clinical trials discussed included: a) lack of access to results of clinical tests conducted during 
clinical trial, b) lack of knowledge of the clinical trial protocol and possible adverse effects, c) 
historical fears based on memory of clinical trial experiences in PR, and d) the notion of being 
guinea pigs. As revealed by both subgroups of participants, their motivations were not directly 
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related with economic benefits or incentives, but might be possibly driven by altruism, which is 
different from the literature as discussed by Townsend and Cox (2013). The precarious status of the 
health system in PR and lack of access to treatments for most of the chronic conditions could explain 
the patients’ motivations. Clinical trials could mean a possible window for these patients to get access 
to health services and innovative treatments. This finding is consistent with recent research that 
concluded that low participation of Latinos in clinical trials is not due to lack of interest, but lack 
of awareness about clinical trials (Arevalo et al., 2016; Lucero, Siddhartha, & Ginossar, 2017).  
A crucial element for this investigation was to understand the motivations and concerns 
that could increase future participation in breast cancer clinical trials of Latina women in the 
context of PR. When analyzing the data, the greatest motivation that the participants expressed 
was to help others, especially other women diagnosed with breast cancer. They often verbalized 
the importance of giving other women hope of a good quality of life or to promote prevention to 
people that have not been diagnosed. This was also represented in terms of their families and the 
possible future health benefits they could obtain through their participation. In contrast with 
another qualitative study about motivations to participate (e.g. Townsend, & Cox, 2013), our study 
participants showed more interest in helping their families and other generations, than in getting 
benefits for themselves. Other recent research studies exploring Latina participation in clinical 
trials agrees with the altruism perspective (London et al., 2015). Possible explanations for the 
altruistic motivation to participate in clinical trials observed in our study may be based on that the 
participants were all women, and in the Latino culture matriarchal characteristics include nurturing 
and taking care of others. 
According to the patriarchal discourse imposed in the Latino culture, women are 
adjudicated responsibilities in the private sphere or domestic/family space (Rivera-Díaz, Varas-
Díaz, Coriano-Ortiz, Padilla, Reyes-Estrada, & Serrano, 2015). They are socialized and taught that 
they are responsible for being the caregivers, assuming this role throughout the process of 
socialization at every stage of their lives. This is also evidenced in the health services scenario, 
including issues regarding family approval for treatment, motherhood responsibilities versus their 
health, among other concerns. A recent research study by Lucero, Siddhartha & Ginossar (2017) 
sustains the idea that involving family members in the clinical trial educational process may help 
participants make better decisions. In terms of clinical trial recruitment, this is an interesting 
finding to consider implementing in order to increase and obtain an effective participation of 
Latinas. Incentives for these women do not mean monetary benefits (London et al., 2015). Having 
access to some services and flexibilities such as flexible time, child care, transportation, and 
clinical interventions at home, unless medical or hospital intervention is required, are more 
effective participation incentives for this population. Also, considerations for providing socio-
emotional support to participants depending the stage of their cancer diagnosis at the time of 
recruitment and research team’s sense of empathy are highlighted. Those factors could play a 
decisive role for their willingness to participate in a clinical trial.   
Also, there is a reality to consider regarding the difficulty in obtaining access to health 
services in the public health system in PR (Gobierno de Puerto Rico, 2005; Muñoz Sosa, Rivera 
Díaz, & Correa Luna, 2018; Rivera Díaz, 2015). It is possible that breast cancer survivors would 
accept to participate due to their capacity to obtain specialized health services such as laboratories, 
and specialized evaluations (82.4% of the participants reported difficulties in obtain health 
services), that otherwise they would not have access to. Not having access to laboratory test results 
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that are part of the clinical trial could be consideration for not participating. Our findings showed 
that education and continuous information about the purpose of the trial and its implications is 
needed to motivate participation. Participants expressed that it would be very difficult for them to 
accept participating in a clinical trial if they were not provided with a complete overview of the 
study.  
 When addressing important factors that determine retention in clinical trials, women from 
both subgroups expressed the need for open and constant communication with the clinical trial 
research team. They would like to be informed on how the research is going, how it will benefit to 
them, and how the objectives will be fulfilled. Physicians and the clinical trial research team should 
be open to interdisciplinary work to help attain the goals of the study. The inclusion of different 
professions, such as social workers, would help on the ongoing process of communication and 
motivation to participate in the trial, by advocating for the patient’s rights in future research. The 
social work profession has the responsibility to advocate for right to health for all individuals, in 
order to promote an illness-free environment and contribute to the eradication of social 
determinants that impact health. Also, social workers in clinical settings could play a potential role 
for providing specific benefits information and to clarify research protocols to patients, facilitate 
access to clinical trials, conduct clinical trials as researchers as well as defend the right of patients 
for health information and access to new treatments through educational intervention models.  
 Some limitations need to be considered in this study. For future studies, inclusion criteria 
should consider the stage of diagnosis of those participants without clinical trial experience. 
Participants with a more recent diagnosis were more emotionally vulnerable during the FG than 
those on remission or those who had finished their treatment. Also, most of the FG (6 out of 7) 
were carried out in one site (hospital), this could have an effect in the variability of the experiences 
reports as women coming from different regions of the country, and with different socioeconomic 
and health insurance coverage backgrounds, may have had different experiences. Despite these 
limitations, our study provides important qualitative data to pursue future studies which promote 
retention and recruitment strategies for clinical trials in the Island. A promising endeavor given 
that most of the participants (63%) reported willingness to participate in a future trials, and that 
most of the barriers discussed by the participants, are manageable and best targeted using a 
multidisciplinary approach.  
 
CONCLUSION 
Based on the findings, we recommend the following ten (10) considerations to recruit and 
effectively retain Puerto Rican women in clinical trials: 1) Consider the personal and work-related 
circumstances of the women (Ex. Productive life, job’s limitations, child care); 2) Identify benefits 
and incentives, in addition to monetary incentives, that could help in recruitment and retention, 
such as access to medical examinations, medical care, and clinical lab results; 3) Involve the 
families in the process of recruitment, education, implementation, and culmination of clinical 
trials, as it might increase the family’s support for the patient in the trial; 4) Consider the stage of 
the cancer when recruiting participants and identify culturally-sensitive ways to work with them; 
5) Educate survivors about the differences between standard of care for their cancer and the 
implications of clinical trial procedures; 6) Develop creative strategies to explain the implications 
of the clinical trial protocols to participants such as radio, non-medical journal announcements 
(magazines) with clinical trial information, educational videos in medical offices, among others ; 
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7) Clarify and provide information about protocols in case of adverse situations or emergencies; 
8) Promote interdisciplinary work. (i.e. the social worker’s role in trial); 9) Develop protocols that 
require the disclosure of study results to participants as part of the IRB protocol. This should 
include publication of results in general and popular magazines using a friendly and accessible 
language; and 10) Encourage the dissemination of the study results through popular access 
platforms. To achieve this, as social scientists, we need to restore the confidence and eradicate the 
misperceptions about clinical trials and the “guinea pig” reference from our popular memory. 
Building a trustworthy relationship between research/recruitment team and patients will enhance 
trust and participation of Latinas in breast cancer clinical trials. Therefore, it will contribute to the 
development of effective prevention, diagnostic, and new treatment interventions, methods, and 
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